Abraxis BioScience Launches Doxorubicin Hydrochloride Injection, USP

  
    
  
  
    
      Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global 
      biopharmaceutical company, today announced that its hospital-based 
      products business, Abraxis Pharmaceutical Products (APP), has launched 
      Doxorubicin Hydrochloride Injection, USP 2mg/mL, the generic equivalent 
      of Adriamycin® PFS 
      which is owned by Bedford Laboratories, a division of Boehringer 
      Ingelheim GmbH. According to IMS, sales in 2006 of doxorubicin 
      hydrochloride injection in the United States exceeded $30 million. 
      Contracts for this product have already been secured and APP expects to 
      immediately commence marketing of Doxorubicin, which is commonly used in 
      the treatment of a wide range of cancers. The product is AP rated, 
      preservative-free and latex-free.
    
    
      Doxorubicin has been used successfully to produce regression in 
      disseminated neoplastic conditions such as acute lymphoblastic leukemia, 
      acute myeloblastic leukemia, Wilms’ tumor, 
      neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian 
      carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, 
      gastric carcinoma, Hodgkin’s disease, 
      malignant lymphoma and bronchogenic carcinoma in which the small cell 
      histologic type is the most responsive compared to other cell types. 
      Doxorubicin is also indicated for use as a component of adjuvant therapy 
      in women with evidence of auxiliary lymph node involvement following 
      resection of primary breast cancer.
    
    
      About Abraxis BioScience, Inc.
    
    
      Abraxis BioScience, Inc. is an integrated global biopharmaceutical 
      company dedicated to meeting the needs of critically ill patients. The 
      company develops, manufactures and markets one of the broadest 
      portfolios of injectable products and leverages revolutionary technology 
      such as its nab™ platform to discover 
      and deliver breakthrough therapeutics that transform the treatment of 
      cancer and other life-threatening diseases. The first FDA approved 
      product to use this nab platform, ABRAXANE®, 
      was launched in 2005 for the treatment of metastatic breast cancer. 
      Abraxis trades on the Nasdaq Global Market under the symbol ABBI. For 
      more information about the company and its products, please visit www.abraxisbio.com.
    
    
      Adriamycin® is a 
      registered trademark of Bedford Laboratories, a division of Boehringer 
      Ingelheim GmbH